SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-23-049319
Filing Date
2023-10-24
Accepted
2023-10-24 16:05:40
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13D/A ef20013034_sc13da.htm SC 13D/A 52875
  Complete submission text file 0001140361-23-049319.txt   54341
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88023 | Film No.: 231342750
SIC: 2834 Pharmaceutical Preparations

Mailing Address RUE DE LYON 105 GENEVA V8 CH 1203
Business Address RUE DE LYON 105 GENEVA V8 CH 1203 41 22 344 96 36
Teoxane SA (Filed by) CIK: 0001992112 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A